In a recent study, anti-Wnt2 mAb was found to significantly restore intratumoral anti-tumor T cell responses and enhance the efficacy of anti-PD-1 by increasing active DCS in both mouse OSCC and CRC syngeneic tumour models. Here, WNT2 is linked to neoplasm.